Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980

Detalles Bibliográficos
Autores principales: Aroda, Vanita R., Rosenstock, Julio, Wysham, Carol, Unger, Jeffrey, Bellido, Diego, González-Gálvez, Guillermo, Takami, Akane, Guo, Hailing, Niemoeller, Elisabeth, Souhami, Elisabeth, Bergenstal, Richard M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2017
Materias:
Errata
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439418/
https://www.ncbi.nlm.nih.gov/pubmed/28428368
http://dx.doi.org/10.2337/dc17-er06d

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439418/
https://www.ncbi.nlm.nih.gov/pubmed/28428368
http://dx.doi.org/10.2337/dc17-er06d

Ejemplares similares